Business Description
Qualigen Therapeutics Inc
NAICS : 541713
SIC : 8731
ISIN : US74754R2022
Share Class Description:
STU:7R9: Ordinary SharesDescription
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.07 | |||||
| Equity-to-Asset | -8.01 | |||||
| Debt-to-Equity | -0.39 | |||||
| Debt-to-EBITDA | -0.21 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -28.2 | |||||
| 3-Year EPS without NRI Growth Rate | -20.9 | |||||
| 3-Year FCF Growth Rate | -165.1 | |||||
| 3-Year Book Growth Rate | 38.2 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.52 | |||||
| 9-Day RSI | 41.33 | |||||
| 14-Day RSI | 43.47 | |||||
| 6-1 Month Momentum % | -48.31 | |||||
| 12-1 Month Momentum % | -75.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.11 | |||||
| Quick Ratio | 0.11 | |||||
| Cash Ratio | 0.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -62.3 | |||||
| Shareholder Yield % | 53.26 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -230.96 | |||||
| ROIC % | -174.06 | |||||
| ROC (Joel Greenblatt) % | -406.56 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.51 | |||||
| EV-to-EBITDA | -0.51 | |||||
| EV-to-Forward-Revenue | 0.01 | |||||
| EV-to-FCF | -0.57 | |||||
| Earnings Yield (Greenblatt) % | -196.08 | |||||
| FCF Yield % | -284.13 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Qualigen Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.623 | ||
| Beta | -0.61 | ||
| Volatility % | 42.21 | ||
| 14-Day RSI | 43.47 | ||
| 14-Day ATR (€) | 0.014085 | ||
| 20-Day SMA (€) | 0.18085 | ||
| 12-1 Month Momentum % | -75.52 | ||
| 52-Week Range (€) | 0.143 - 0.982 | ||
| Shares Outstanding (Mil) | 12.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Qualigen Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Qualigen Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Qualigen Therapeutics Inc Frequently Asked Questions
What is Qualigen Therapeutics Inc(STU:7R9)'s stock price today?
The current price of STU:7R9 is €0.17. The 52 week high of STU:7R9 is €0.98 and 52 week low is €0.14.
When is next earnings date of Qualigen Therapeutics Inc(STU:7R9)?
The next earnings date of Qualigen Therapeutics Inc(STU:7R9) is 2024-08-21 Est..
Does Qualigen Therapeutics Inc(STU:7R9) pay dividends? If so, how much?
Qualigen Therapeutics Inc(STU:7R9) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers